Tender Details

Country: USA
Summary: Development of Radiation/Nuclear Medical Countermeasures (MCMs) And Biodosimetry Devices
UST Ref No: 112117238
Deadline: 19 Mar 2025
Financier: Self Financed
Purchaser Ownership: Government
Tender Value: Refer Document
Notice Type: Tender
Document Ref. No.: BAA-75N93024R00020
Purchaser's Detail:
Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
Login to see details
Description:
Description
Radiological/nuclear incidents can potentially result in the exposure of large numbers of civilians to a high dose of radiation in a short period of time. Depending on the dose and proportion of wholebody exposure to external radiation, biological effects can range from acute complications (acute radiation syndrome, ARS), including nausea and vomiting within hours; hematopoietic and gastrointestinal (GI) injuries leading to immunosuppression, infections, hemorrhage, and death within days to weeks; to delayed effects of acute radiation exposure (DEARE) in ARS survivors, including cutaneous, pulmonary, cardiovascular, central nervous system, or renal complications months to years after irradiation.
The U.S. Government recognizes the need to develop medical countermeasures (MCMs) (e.g., drugs, biologics, cell, or cell products) and biodosimetry devices to address radiation-induced biological injuries sustained during a radiological or nuclear incident. To this end, the Project BioShield Act of 2004, Public Law 108-276, was enacted. This Act provides the Department of Health and Human Services (HHS) with authorities to procure MCMs for the Strategic National Stockpile (SNS) and to perform advanced research and development on priority MCMs against chemical, biological, radiological, and nuclear threats. Under this act, the Radiation and Nuclear Countermeasures Program (RNCP) within NIAID was created and charged by HHS, on behalf of theNational Institutes of Health (NIH), to address radiation-induced injuries resulting from a radiation public health emergency, with funds provided to the NIH from a special congressional appropriation.
The coordinated efforts to support radiation research and development by the NIH, as well as other HHS agencies, are outlined in the HHS Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Strategy and Implementation Plan. The NIH is committed to accelerating the development of drugs and biologics to tr...
Documents:

BAA-75N93024R00020-Development-of-Radiation-Nuclea.pdf

If you are registered member, kindly login to view full details of this tender notice:

Development of Radiation/Nuclear Medical Countermeasures (MCMs) And Biodosimetry Devices - USA Tender

The HEALTH AND HUMAN SERVICES, DEPARTMENT OF | NATIONAL INSTITUTES OF HEALTH, a Government sector organization in USA, has announced a new tender for Development of Radiation/Nuclear Medical Countermeasures (MCMs) And Biodosimetry Devices. This tender is published on USARFP under UST Ref No: 112117238 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2025-03-19.

The estimated tender value is Refer Document, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.